Authors
Kalinin R.E.1, Suchkov I.A.1, Karpov V.V.1, 2, Egorov A.A.1, Avezov A.T.1, 2, Karpov D.V.1, 2
1 Ryazan State Medical University named after Academician I. P. Pavlov, Ryazan
2 Regional Clinical Hospital, Ryazan
Abstract
Background: Chronic kidney disease is widespread (10-13% of the world’s population), irreversible, progressive, and associated with an increased risk of cardiovascular disease. Every year, there are 10-12% more patients with end-stage renal failure. They are shown renal replacement therapy by conducting programmed hemodialysis through permanent vascular access.
Aims: to evaluate the results of the use of freshly prepared venous homographs in the formation of permanent vascular access in patients with stage V chronic kidney disease, in comparison with the use of synthetic prostheses.
Materials and methods: A retrospective study included 40 patients with stage V CKD who underwent PSA formation with a synthetic prosthesis (SSP) and venous femoral vein homograft. Depending on the material used, 2 groups were formed: group 1 – SSP was used (n = 22), group 2 – femoral vein homograph was used (n = 18). Homograft was used in patients after SSP thrombosis and/or with paraprosthetic access infection. In patients after the formation of PSD (synthetic conduit and venous homograph) in the postoperative period, the following were assessed: primary patency after 1.5 months, 3 months, 6 months, 9 months and 12 months after the formation of access, complications during puncture and needle extraction, and the level of recirculation 12 months after the formation of access. The frequency of formation of aneurysms of biological conduits has been studied. The total follow-up period for patients after the formation of PSD (synthetic conduit and venous homograph) was 1 year.
Results: The patency of permanent vascular access after 12 months in the first group was 86%, the patency of permanent vascular access after 12 months in the second group was 94%. There was no statistically significant difference in the patency of permanent vascular access between the groups (P = 0.82). During puncture and needle extraction, no bleeding was observed from the homograph during hemodialysis during the follow-up period. There was no significant level of recycling in both groups by the end of the study (14±5.1% in the group of synthetic vascular prostheses (SSP) and 16±4.2% in the group of homographs). No aneurysmal transformation of homographs was detected during the 12 months of follow-up.
Conclusions: The formation of PSD by venous homograft can be considered an acceptable alternative to synthetic conduit.
Keywords: homograph, permanent vascular access for hemodialysis, stage V chronic kidney disease, RPMI 1640 solution.
References
1. Ammirati AL. Chronic Kidney Disease. Rev Assoc Med Bras (1992). 2020 Jan 13; 66(S1): s03-s09. doi: 10.1590/1806-9282.66.S1.3.
2. Naber T, Purohit S. Chronic Kidney Disease: Role of Diet for a Reduction in the Severity of the Disease. Nutrients. 2021; 13(9): 3277. doi: 10.3390/ nu13093277.
3. Higuchi T, Okuda N, Aoki K, et al. Intravascular ultrasound imaging before and after angioplasty for stenosis of arteriovenous fistula in hemodialysis is patients. Nephrol Dial Transplant. 2001; 16(1): 151-5.
4. Tokars JI, Light P, Anderson J, et al. A prospective study of vascular access infections at seven outpatient hemodialysis centers. Am J Kidney Dis. 2001; 37(6): 1232-40.
5. Stehman-Breen CO, Sherrard DJ, Gillen D, Caps M. Determinants of type and timing of initial permanent hemodialysis vascular access. Kidney Int. 2000; 57(2): 639-45.
6. Krupatkin VV. Clinical hemostasiology and hemorheology in cardiovascular surgery: materials of the VII all-Russian conference with international participation. Moscow, 2015. P.221. (In Russ.)
7. Lindsay RM, Leypoldt JK. Monitoring vascular access flow. Adv Ren Replace Ther. 1999; 6(3): 273-7.
8. García-Jérez A, Luengo A, Carracedo J, et al. Effect of uraemia on endothelial cell damage is mediated by the integrin linked kinase pathway. J Physiol. 2015; 593(3): 601-18.
9. Kalinin RE, Suchkov IA, Egorov AA. Possibilities of roentgen-endovascular and hybrid correction of permanent vascular access in dialysis-dependent patients. Science of the young (Eruditio Juvenium). 2018; 6(4): 561-8. (In Russ.) doi: 10.23888/HMJ201864561-568.
10. Kalinin RE, Suchkov IA, Pshennikov AS. Reperfusion injury of tissues in lower limb arterial reconstructive surgery. Novosti Khirurgii 2015; 23(3): 348-352 (In Russ.) doi: 10.18484/ 2305-0047.2015.3.348.
11. Nassar GM, Ayus JC. Infectious complications of the hemodialysis access. Kidney Int. 2001; 60(1): 1-13.
12. Moisyuk YaG, Belyaev AYu, Inozemtsev AS, et al. Permanent vascular access for hemodialysis: current trends. Nephrology and dialysis/ 2002; 4(1): 14-24 (In Russ.)
13. Kalinin RE, Suchkov IA, Karpov VV, Egorov AA. The use of allografts in the surgical treatment of popliteal artery aneurysms. Russian Medical and Biological Bulletin named after academician I.P. Pavlov. 2022; 30(1): 115-122. (In Russ.)
14. Kalinin RE, Suchkov IA, Egorov AA, Medvedeva OV. Examples of non-standard reconstructions in hemodialysis patients with permanent vascular access. Novosti Khirurgii. 2017; 25(1): 87-92. (In Russ.) doi: 10.18484/2305-0047.2017.1.87.
15. Kalinin RE, Suchkov IA, Egorov AA, Kaprov VV, Klimentova EA, Karpov DV. Permanent vascular access for hemodialysis using allogeneic vein. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2021; 14(1): 98‑103. (In Russ.) doi: 10.17116/kardio20211401198.
16. Madden R, Lipkowitz G, Benedetto B, et al. Decellularized Cadaver Vein Allografts Used for Hemodialysis Access Do Not Cause Allosensitization or Preclude Kidney Transplantation. Am J Kidney Dis. 2002; 40(6): 1240-3. doi: 10.1053/ajkd.2002.36892.
17. Benedetto B, Lipkowitz G, Madden R, et al. Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitization. Vasc Surg. 2001; 34(1): 139-42. doi: 10.1067/mva.2001.114206.
18. Kamyar M.M., Saeed Modaghegh M.H., Kazemzadeh G. Limb complaints after autogenous arteriovenous fistula creation in chronic hemodialysis patients. Semin Vasc Surg. 2016; 29(4): 172-177.
19. Belyaev AYU. Sovremennye tendencii v sozdanii sosudistogo dostupa dlya gemodializa. Nefrologiya i dializ. 2007; 9(4): 386-391. (In Russ.)
20. Yang B, Brahmbhatt A, Nieves Torres E, et al. Tracking and Therapeutic Value of Human Adipose Tissue-derived Mesenchymal Stem Cell Transplantation in Reducing Venous Neointimal Hyperplasia Associated with Arteriovenous Fistula. Radiology. 2016; 279(2): 513-22.
21. Cinat ME, Hopkins J, Wilson SE. A prospective evaluation of PTFE graft patency and surveillance techniques in hemodialysis access. Ann Vasc Surg. 1999; 13(2): 191-8.
22. Ding X, Chen J, Wu C, et al. Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3 Deficiency in Vascular Smooth Muscle Cells Prevents Arteriovenous Fistula Failure Despite Chronic Kidney Disease. J Am Heart Assoc. 2019; 8(1): e011211.
23. Akoh JA. Vascular access infections: epidemiology, diagnosis, and management. Curr Infect Dis Rep. 2011; 13(4): 324-332.
24. Caroline C Jadlowiec, Matthew Lavallee, Elizabeth M Mannion, Matthew G Brown. An Outcomes Comparison of Native Arteriovenous Fistulae, Polytetrafluorethylene Grafts, and Cryopreserved Vein Allografts. Vasc Surg. 2015; 29(8): 1642-7. doi: 10.1016/j.avsg.2015.07.009.
